StudyRareStudyRare

Cancer Predisposition Syndromes

25 conditions|15 ABGC-listed

Overview

Hereditary cancer syndromes represent ~5-10% of all cancers. Key concepts include tumor suppressor genes (two-hit hypothesis), DNA repair pathways, and the importance of early detection through surveillance protocols.

Cancer risk exists on a spectrum from population-level risk (driven by age and sex) to polygenic risk (family history, common variants) to monogenic risk (single high-penetrance genes like BRCA1). Understanding where a patient falls on this spectrum guides testing and management decisions.

Cancer risk spectrum
Cancer risk spectrum

Genetic testing in oncology falls into two categories: germline testing (blood/saliva) identifies inherited cancer risk for the patient and their family, while somatic testing (tumor tissue) identifies acquired variants that may guide treatment. Both may be relevant for a single patient.

Germline vs somatic genetic testing
Germline vs somatic genetic testing

Colorectal cancer

The key distinction is between polyposis (FAP and MUTYH, with adenomatous polyps) and non-polyposis (Lynch, with mismatch repair deficiency and MSI-high tumors). FAP has 100% CRC risk without colectomy. Lynch syndrome (MMR genes) also causes endometrial and ovarian cancers. Peutz-Jeghers (lip pigmentation, hamartomas) has broad cancer risks. MUTYH is the only AR polyposis syndrome, requiring biallelic variants.

Other cancer predisposition syndromes

This section covers syndromes that don't fit the above categories. VHL (hypoxia sensing pathway) causes hemangioblastomas + clear cell RCC + pheochromocytoma. The renal cancer syndromes map to distinct histologies: VHL = clear cell, HLRCC = aggressive papillary (no nephron-sparing!), BHD = chromophobe + pneumothorax. Gorlin (PTCH1, Hedgehog pathway) causes multiple BCCs and medulloblastoma; avoid radiation.

Summary Table

SyndromeGeneInheritanceKey Cancers
HBOCBRCA1/2ADBreast, ovarian, prostate, pancreatic
CHEK2CHEK2ADBreast (moderate penetrance), often HR+
PALB2PALB2ADBreast (high), pancreatic, ovarian
LynchMLH1, MSH2, MSH6, PMS2ADColorectal, endometrial, ovarian
FAPAPCADColorectal (100%), desmoids
MAPMUTYHARColorectal
Peutz-JeghersSTK11ADGI, breast, pancreatic, ovarian
Juvenile polyposisSMAD4, BMPR1AADColorectal, gastric; SMAD4 + HHT
Cowden / PHTSPTENADBreast, thyroid, endometrial
HDGCCDH1ADDiffuse gastric, lobular breast
GAPPSAPC promoter 1BADGastric (fundic polyps), no colon
MEN1MEN1ADParathyroid, pituitary, pancreatic NET
MEN2RETADMedullary thyroid, pheochromocytoma
HPGL/PCCSDHxADParaganglioma, pheochromocytoma
Li-FraumeniTP53ADSarcoma, breast, brain, adrenocortical
CMMRDbiallelic MMRARChildhood brain/heme/GI; café-au-lait
BloomBLMARLeukemia, lymphoma, solid tumors
WernerWRNARSarcomas, melanoma, thyroid
Xeroderma pigmentosumXP genesARBCC, SCC, melanoma (1000x risk)
FAMMMCDKN2AADMelanoma, pancreatic cancer
VHLVHLADRCC, hemangioblastoma, pheochromocytoma
HLRCCFHADType 2 papillary RCC, cutaneous/uterine leiomyomas
Hereditary papillary RCCMETADType 1 papillary RCC, bilateral/multifocal
BHDFLCNADRCC (chromophobe), pneumothorax
GorlinPTCH1ADBCC, medulloblastoma

Key Genetic Counseling Points for Cancer Syndromes

  1. Risk assessment tools: BRCAPRO, Tyrer-Cuzick, MMRpro, etc.
  2. Testing strategy: Start with affected individual when possible
  3. Variant interpretation: VUS management and reclassification
  4. Cascade testing: Identify at-risk family members
  5. Psychosocial considerations: Survivor guilt, insurance/discrimination (GINA)
  6. Reproductive options: PGT-M, prenatal diagnosis
  7. Surveillance vs. risk reduction: Shared decision-making